Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infections in Indonesia

Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.

Recce Pharmaceuticals has commenced patient dosing in its Registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia, with five clinical sites activated. This trial, one of the largest DFI studies globally, aims to assess the efficacy of RECCE 327 Topical Gel (R327G) and is expected to have interim results by Q1 2026. The trial is strategically significant given Indonesia’s high diabetes prevalence, representing a substantial market opportunity. Successful results could lead to accelerated approval and a potential commercial launch in 2026, positioning Recce as a key player in addressing diabetes-related infections.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

More about Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd is a leading developer of a new class of synthetic anti-infectives. The company focuses on creating innovative broad-spectrum therapies to address infections related to diabetes, urinary tract infections, and surgical site infections. Recce is positioned to tackle the infectious disease challenges associated with the global rise in diabetes.

Average Trading Volume: 120,041

Technical Sentiment Signal: Hold

Current Market Cap: A$114.2M

Find detailed analytics on RCE stock on TipRanks’ Stock Analysis page.